Literature DB >> 1423235

Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells.

P E Nisson1, P C Watkins, N Sacchi.   

Abstract

In the t(8;21)(q22;q22) of acute myelogenous leukemia (AML), the breakpoint on chromosome 21 disrupts the AML1 gene, generally in the intron between exons 5 and 6. To isolate fusion transcripts of AML1, and an as yet unidentified gene on chromosome 8 involved in the rearrangement, we used rapid amplification of cDNA ends (RACE) and primers for AML1 exons 5 and 6. A fusion transcript was identified by 3' RACE in the RNA of t(8;21) leukemic cells that also express multiple normal AML1 transcripts. This result clearly indicates that at least one transcriptionally active chimeric gene is generated by the chromosome translocation. This gene on the 8q- derivative represents the fusion between the 5' portion of the AML1 gene with the 3' portion of a chromosome 8 gene that contains a region of sequence homology with the cyclin D2 gene, here referred to as the CDR gene (cyclin D-related gene). The chimeric gene is probably responsible for the pathogenesis of the 8;21 AML. This finding makes it possible to detect the translocation at the molecular level, thus improving the diagnosis and monitoring of the disease in leukemic patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423235     DOI: 10.1016/0165-4608(92)90384-k

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  38 in total

1.  Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.

Authors:  Ming Yan; Sebastien A Burel; Luke F Peterson; Eiki Kanbe; Hiromi Iwasaki; Anita Boyapati; Robert Hines; Koichi Akashi; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

Review 2.  Developmental relationship between hematopoietic and endothelial cells.

Authors:  Jesse J Lugus; Changwon Park; Kyunghee Choi
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.

Authors:  S W Hiebert; W Sun; J N Davis; T Golub; S Shurtleff; A Buijs; J R Downing; G Grosveld; M F Roussell; D G Gilliland; N Lenny; S Meyers
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

4.  Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1.

Authors:  M S Petrovick; S W Hiebert; A D Friedman; C J Hetherington; D G Tenen; D E Zhang
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

Review 5.  AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Authors:  Megan A Hatlen; Lan Wang; Stephen D Nimer
Journal:  Front Med       Date:  2012-08-09       Impact factor: 4.592

6.  Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation.

Authors:  I Kitabayashi; A Yokoyama; K Shimizu; M Ohki
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

7.  Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.

Authors:  Miao-Chia Lo; Luke F Peterson; Ming Yan; Xiuli Cong; Fulai Jin; Wei-Jong Shia; Shinobu Matsuura; Eun-Young Ahn; Yukiko Komeno; Minh Ly; Hans B Ommen; I-Ming Chen; Peter Hokland; Cheryl L Willman; Bing Ren; Dong-Er Zhang
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

8.  Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis.

Authors:  K L Rhoades; C J Hetherington; J D Rowley; S W Hiebert; G Nucifora; D G Tenen; D E Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

9.  Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins.

Authors:  Kojo S J Elenitoba-Johnson; David K Crockett; Jonathan A Schumacher; Stephen D Jenson; Cheryl M Coffin; Alan L Rockwood; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

10.  PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials.

Authors:  S C Bae; E Ogawa; M Maruyama; H Oka; M Satake; K Shigesada; N A Jenkins; D J Gilbert; N G Copeland; Y Ito
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.